SFTS Patient Mortality Predictors with IL-6/LY Ratio

495 patients from two Chinese hospitals between January 2022 and October 2025 were studied to identify prognostic factors for Severe Fever with Thrombocytopenia Syndrome mortality. The dataset includes predictors like DBV RNA level, age, and the interleukin-6-to-lymphocyte ratio (IL-6/LY). It was used in a discovery and validation study to assess the prognostic value of IL-6/LY for early mortality.

Use Cases

• Train a mortality prediction model using IL-6/LY ratio, DBV RNA level, and age as features on 495 patient records.
• Validate prognostic performance of the IL-6/LY ratio by analyzing its area under the ROC curve (AUC) across training and external cohorts.
• Conduct survival analysis using the Kaplan–Meier method to compare survival probability between patient groups stratified by IL-6/LY levels.
• Perform decision curve analysis (DCA) to evaluate the clinical benefit of using IL-6/LY for mortality prediction in SFTS patients.

Strengths

• Multicenter cohort design with 495 total patient records.
• Includes both a training cohort (323 patients) and an external validation cohort (172 patients).
• Identifies specific prognostic factors with quantified performance (e.g., IL-6/LY AUC of 0.839 in training).

Limitations

• Data is contained within a research paper (DOCX), requiring extraction for tabular analysis.
• Patient cohort is geographically limited to two hospitals in China.
• The 691.1 KB file size suggests the dataset is small in scale, likely containing summary statistics rather than raw patient-level data.

Provenance

Source

Wan Peng, via figshare.

Collection Method

Multicenter cohort study from Yantai Qishan Hospital and Qingdao No. 6 People’s Hospital.

Time Range

January 2022 to October 2025.

Freshness

Data covers patients up to October 2025, with the dataset last updated in March 2026.

Geography

China (Yantai and Qingdao).